Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 26 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.
Preservative: 0.02% Proclin 300
Constituents: PBS
ELISA | I-ELISA | |
---|---|---|
Recombinant fragment - SARS-CoV-2 | Not recommended | Tested |
Recombinant full length protein - SARS-CoV | Tested | Not recommended |
Recombinant full length protein - SARS-CoV-2 | Tested | Not recommended |
SARS-CoV | Predicted | Predicted |
SARS-CoV-2 | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV, SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV, SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV | Dilution info - | Notes - |
Select an associated product type
Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:32155444, PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32075877, PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270). Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 26 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.
Preservative: 0.02% Proclin 300
Constituents: PBS
The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes (16796401).
CR3022 has been shown to bind with a high affinity to SARS-CoV2 (32416259, 32413276). Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain (32245784, 32065055). Precisely, this antibody binds to the 'open' conformation of the spike protein to the amino acids 318-510 in the S1 domain of the SARS-CoV as well as SARS-CoV-2 strains (32245784, Joyce et al. 2020). The antibody is also able to bind the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope of clone CR3022 does not overlap with the ACE2 binding site of SARS-COV2 (32065055). Therefore whilst CR3022 can neutralise SARS-COV in in a concerted action with clone CR3014, CR3022 is not believed to independently neutralise SARS-COV2, based on in vitro studies (32226289, 32065055, 32383254, 32416259).
Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (ab273073) is a Human IgG1 Recombinant version of CR3022 for research use only. CR3022 is also available as a chimeric rabbit antibody (Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rabbit IgG (Chimeric) ab273074).
Applications overview
Tick: Tested and Guaranteed to work X: Will not work —: No data
ab273073 was developed to have a human IgG1 isotype.
Other isotypes of clone CR3022 available:
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] ab278112 – human IgA
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] ab278111 – human IgM
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rabbit IgG (Chimeric) ab273074 – rabbit IgG
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rat IgG2a (Chimeric) ab273886 – rat IgG2a
The SARS-CoV-2 Spike Glycoprotein S1 also known as the G10 spike or glycoprotein spike plays an important role in allowing the virus to attach and enter host cells. This protein with a mass of approximately 180 kDa is located on the surface of the virus and forms the outer spikes observed in coronaviruses. Expression of the spike glycoprotein is in virus-infected cells where it facilitates the interaction with host cell receptors. The S1 subunit includes a receptor-binding domain that specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptors initiating the infection process.
The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.
The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.
Infection with the spike glycoprotein S1 is directly related to COVID-19. The binding to ACE2 receptors is linked to the pathology of the disease contributing to respiratory symptoms and in severe cases acute respiratory distress syndrome (ARDS). Through the IL-6 signaling pathway the spike protein is indirectly connected to cytokine release syndrome often observed in severe COVID-19 cases. This connection highlights the importance of targeting this glycoprotein for potential therapeutic interventions and diagnostics such as ELISA SARS-CoV-2 tests and the development of anti-spike antibodies available on platforms like antispark.com for research and clinical purposes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ELISA using ab273073 and mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. RBD WT – wild-type receptor binding domain.
Indirect ELISA showing primary antibody ab273073 (CR3022, human chimeric) binding to the antigens Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) and Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active)). Plates were coated with 100ng/well Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 or Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068 and binding of ab273073 assessed in serial dilution from 200ng/ml primary antibody in duplicate. Binding was detected using Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
ELISA using ab273073 with UK (B.1.1.7) and South African (B.1.351 (501Y.V2)) mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. WT – wild type.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) at concentrations of 5 μg/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells at concentrations of 5 μg/ml. A 3-fold serial dilution from 125 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com